tiprankstipranks
Advertisement
Advertisement

PHVS Stock Latest News

Pharvaris: Dual IR+XR Deucrictibant Strategy Supports Overweight Rating on Safety, Efficacy, and Differentiation
RatingsPharvaris: Dual IR+XR Deucrictibant Strategy Supports Overweight Rating on Safety, Efficacy, and Differentiation
19d ago
PHVS
Pharvaris presents data from deucrictibant IR capsule and XR tablet study
PremiumThe Fly
Pharvaris presents data from deucrictibant IR capsule and XR tablet study
20d ago
PHVS
Pharvaris price target raised to $52 from $48 at JonesResearch
PremiumThe Fly
Pharvaris price target raised to $52 from $48 at JonesResearch
25d ago
PHVS
Pharvaris: Deucrictibant Data, Strengthened HAE Pipeline, and Extended Cash Runway Support Higher $52 DCF-Based Target and Buy Rating
PremiumRatings
Pharvaris: Deucrictibant Data, Strengthened HAE Pipeline, and Extended Cash Runway Support Higher $52 DCF-Based Target and Buy Rating
25d ago
PHVS
3 ‘Perfect 10’ Smart Score Stocks to Buy this Week, 4/13/26, According to Analysts
PremiumMarket News
3 ‘Perfect 10’ Smart Score Stocks to Buy this Week, 4/13/26, According to Analysts
27d ago
ANET
BCRX
Texas Instruments upgraded, Circle downgraded: Wall Street’s top analyst calls
PremiumThe FlyTexas Instruments upgraded, Circle downgraded: Wall Street’s top analyst calls
1M ago
KR
ZS
Pharvaris initiated with an Outperform at Wolfe Research
Premium
The Fly
Pharvaris initiated with an Outperform at Wolfe Research
1M ago
PHVS
Pharvaris price target raised to $42 from $41 at Wedbush
Premium
The Fly
Pharvaris price target raised to $42 from $41 at Wedbush
1M ago
PHVS
Pharvaris: Late-Stage Deucrictibant Progress, Expansion into Untreated Angioedema Markets, and Solid Cash Runway Underpin Buy Rating and $60 Target
PremiumRatings
Pharvaris: Late-Stage Deucrictibant Progress, Expansion into Untreated Angioedema Markets, and Solid Cash Runway Underpin Buy Rating and $60 Target
1M ago
PHVS
Pharvaris price target lowered to $51 from $52 at RBC Capital
PremiumThe Fly
Pharvaris price target lowered to $51 from $52 at RBC Capital
1M ago
PHVS
Pharvaris Posts 2025 Results as Deucrictibant Nears NDA Filing and Key Phase 3 Data
PremiumCompany Announcements
Pharvaris Posts 2025 Results as Deucrictibant Nears NDA Filing and Key Phase 3 Data
1M ago
6K
PHVS
Pharvaris reports Q4 EPS (EUR 0.72) vs. (EUR 0.64) last year
PremiumThe Fly
Pharvaris reports Q4 EPS (EUR 0.72) vs. (EUR 0.64) last year
1M ago
PHVS
Pharvaris announces publications of efficacy, safety evidence on deucrictibant
PremiumThe FlyPharvaris announces publications of efficacy, safety evidence on deucrictibant
2M ago
PHVS
Pharvaris reports results from study of patient experience during HAE attacks
Premium
The Fly
Pharvaris reports results from study of patient experience during HAE attacks
2M ago
PHVS
Pharvaris initiated with an Outperform at RBC Capital
Premium
The Fly
Pharvaris initiated with an Outperform at RBC Capital
2M ago
PHVS
Pharvaris participates in a conference call hosted by Cantor Fitzgerald
PremiumThe Fly
Pharvaris participates in a conference call hosted by Cantor Fitzgerald
3M ago
PHVS
Pharvaris: Multiple Late‑Stage Catalysts, Differentiated Oral HAE Franchise, and Solid Cash Runway Support Buy Rating and $48 Target
PremiumRatings
Pharvaris: Multiple Late‑Stage Catalysts, Differentiated Oral HAE Franchise, and Solid Cash Runway Support Buy Rating and $48 Target
4M ago
PHVS
Pharvaris Sets 2026 Roadmap as Deucrictibant Advances Toward NDA Filing and Phase 3 Readouts
PremiumCompany Announcements
Pharvaris Sets 2026 Roadmap as Deucrictibant Advances Toward NDA Filing and Phase 3 Readouts
4M ago
6K
PHVS
3 ‘Strong Buy’ Biotech Stocks to Buy Now, According to Top Analysts
PremiumMarket News
3 ‘Strong Buy’ Biotech Stocks to Buy Now, According to Top Analysts
5M ago
IMNM
KYTX
Pharvaris price target raised to $50 from $44 at Oppenheimer
PremiumThe FlyPharvaris price target raised to $50 from $44 at Oppenheimer
5M ago
KALV
PHVS
Pharvaris price target raised to $39 from $32 at Guggenheim
Premium
The Fly
Pharvaris price target raised to $39 from $32 at Guggenheim
5M ago
PHVS
Pharvaris’s Deucrictibant: Promising Efficacy Amidst Uncertain Market Prospects
Premium
Ratings
Pharvaris’s Deucrictibant: Promising Efficacy Amidst Uncertain Market Prospects
5M ago
PHVS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >